Table 1 Comparison of baseline characteristics between patients with no prestroke statins use prestroke statins use groups
| Â | No prestroke statins use group (136) | Prestroke Statins use group (106) | OR(95% CI) | P* |
|---|---|---|---|---|
Age, y (Mean SD) | 66.1 ± 10.5 | 67.2 ± 9.9 |  | 0.303 |
NIHSS score, median (IQR) | 11 (7–14) | 8(6–12) |  | 0.041 |
Mean AF duration, m (Mean SD) | 67.7 ± 10.0 | 67.8 ± 11.3 |  | 0.915 |
CHA2DS2-VASc, median (IQR) | 4(3–5) | 4(3–5) |  | 0.090 |
Females, n (%) | 66 (48.5%) | 58 (54.7%) | 1.29 (0.77–2.13) | 0.339 |
Men, n (%) | 70 (51.5% | 48 (45.3%) | 1.29 (0.77–2.13) | 0.339 |
BMI ≥ 24 kg/m, n (%) | 36 (26.5%) | 37 (34.9%) | 1.50 (0.86–2.59) | 0.156 |
Hypertension, patients, n (%) | 90 (66.8%) | 79 (74.5%) | 1.50 (0.85–2.63) | 0.160 |
Current Smoking, n (%) | 46 (33.8%) | 30 (28.3%) | 0.77 (0.45–1.34) | 0.359 |
Current alcohol consumption, n (%) | 41 (30.2%) | 24 (22.6%) | 0.67 (0.38–1.22) | 0.191 |
Diabetes, n (%) | 37 (27.2%) | 31 (29.2%) | 1.11 (0.63–1.94) | 0.736 |
Hyperlipidemia, n (%) | 40 (29.4%) | 79 (74.5%) | 7.02 (3.96–12.4) | < 0.001 |
AF Type | ||||
 Paroxysmal, n (%) | 47(34.6) | 38(35.8) | 0.95(0.56–1.61) | 0.835 |
 Permanent, n (%) | 89(65.4) | 68(64.2) | 0.95(0.56–1.61) | 0.835 |
 Family history of stroke, n (%) | 28 (20.6%) | 23 (21.7%) | 1.07 (0.57–1.99) | 0.834 |
 Ox-LDL,U/L (Mean SD) | 37.6 ± 5.1 | 33.5 ± 5.5 |  | < 0.001 |
Medication use | ||||
 Warfarin, n (%) | 20 (14.7%) | 19 (17.9%) | 1.27 (0.64–2.52) | 0.499 |
 direct oral anticoagulants, n (%) | 10(7.4%) | 8(7.5%) | 1.03(0.39–2.70) | 0.954 |
 antiplatelets, n (%) | 25(18.4) | 15(14.2) | 0.73(0.36–1.45) | 0.379 |
 Antihypertensive, n (%) | 76 (55.9%) | 58 ((54.7%) | 0.95 (0.57–1.59) | 0.856 |